Oditrasertib

Oditrasertib (SAR443820) is an orally active, BBB-penetrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis[1][2][3].

Product Specifications

CAS Number

[2252271-93-3]

Product Name Alternative

SAR443820; DNL788

UNSPSC

12352005

Target

RIP kinase

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/oditrasertib.html

Purity

99.24

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#CC1=CN=CC2=C1OCCN(C2)C(C(C)(C(F)F)C)=O

Molecular Formula

C14H15F2N3O2

Molecular Weight

295.28

References & Citations

[1]Fidalgo JDV, et al. Preparation of substituted oxazepines and related compounds as RIPK1 inhibitors and uses thereof. WO2018213632A1. 2018-11-22. |[2]Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17 (1) :e13690. |[3]Montalban X, et al. Effect of RIPK1 inhibitor, SAR443820, on serum neurofilament light levels in patients with multiple sclerosis: a phase 2 trial design (P6-3.011) [J]. Neurology, 2023, 100 (17_supplement_2) : 2178.|[4]Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17 (1) :e13690.